Compass Therapeutics, Inc. (CMPX) NASDAQ
1.97
+0.1(+5.35%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.97
+0.1(+5.35%)
Currency In USD
Address
80 Guest Street
Boston, MA 02135
United States of America (the)
Phone
617 500 8099
Sector
Healthcare
Industry
Biotechnology
Employees
35
First IPO Date
April 05, 2021
| Name | Title | Pay | Year Born |
| Thomas J. Schuetz | Chief Executive Officer & Vice Chairman | 1.03M | 1961 |
| Bing Gong | Chief Scientific Officer | 445,500 | 1976 |
| Jonathan Anderman | Senior Vice President, General Counsel & Corporate Secretary | 648,000 | 1983 |
| Barry Shin | Chief Financial Officer | 717,000 | 1972 |
| Anna Gifford | Senior Manager of Communications & Chief of Staff | 0 | N/A |
| Neil L. Lerner | Senior Vice President & Chief Accounting Officer | 0 | 1967 |
| Karin Herrera | Senior Vice President & Head of Clinical Operations | 0 | N/A |
| Cynthia A. Sirard | Chief Medical Officer | 0 | 1970 |
| James Kranz | Vice President and Head of Chemistry Manufacturing & Controls | 0 | N/A |
| Arjun Prasad | Chief Commercial Officer | 0 | 1978 |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.